Literature DB >> 27899520

Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated With Different Outcomes Among Patients With Venous Thromboembolism?

Alex C Spyropoulos1, Ron Preblick2, Winghan J Kwong2, Melissa Lingohr-Smith3, Jay Lin3.   

Abstract

Clinical and economic outcomes associated with venous thromboembolism (VTE) patient adherence to the American College of Chest Physicians (ACCP) anticoagulant (AC) treatment guidelines are incompletely understood. Patients with ≥1 inpatient or ≥2 separate outpatient claims for deep vein thrombosis and/or pulmonary embolism, based on International Classification of Diseases, Ninth Revision, Clinical Modification codes, were identified from the IMS PharMetrics Plus database. Patients had continuous insurance coverage for 12 months before (baseline) and after (follow-up) the index event (first VTE claim) but no baseline VTE claims. The ACCP recommends minimum AC treatment durations (3 or ≥6 months) dependent upon patient risk profiles. Patients were grouped into study cohorts based on their adherence status (adherent vs nonadherent) to the recommended minimum treatment durations. Patient baseline characteristics, health-care resource utilization, and associated costs were evaluated. The VTE recurrence and bleed-related hospitalization were measured during follow-up. Multivariate regression analysis was utilized to compare clinical and economic outcomes of cohorts. Of the 81 827 study patients, 74% (n = 60 550) were AC adherent. After controlling for key patient characteristics, risks for all-cause hospitalization (adjusted odds ratio [AOR]: 0.85, P < .0001), VTE recurrence (AOR = 0.92, P = .0014), and bleeding-related hospitalization (AOR = 0.74, P < .0001) were lower among adherent patients, as were all-cause health-care cost (-US$2121, P = .0003) and VTE-related (-US$2294, P < .0001) and bleed-related (-US$248, P < .0001) medical costs during the follow-up period. Approximately one-quarter of the study population was AC nonadherent; these nonadherent patients had more VTE recurrences, utilized more inpatient services, and had higher health-care costs.

Entities:  

Keywords:  ACCP; anticoagulants; health-care utilization; oral anticoagulation duration; venous thromboembolism

Mesh:

Substances:

Year:  2016        PMID: 27899520     DOI: 10.1177/1076029616680475

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  5 in total

1.  Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study.

Authors:  Vincent Ten Cate; Anthonie W A Lensing; Jeffrey I Weitz; Jan Beyer-Westendorf; Philip S Wells; Patrick Mismetti; Paolo Prandoni; Alexander T Cohen; Bruce L Davidson; Martin H Prins
Journal:  Haematologica       Date:  2019-03-07       Impact factor: 9.941

2.  Cancer-associated venous thromboembolism in Israel: Incidence, risk factors, treatment, and health care utilization in a population based cohort study.

Authors:  Sarah Sharman Moser; Galia Spectre; Pia Raanani; Orr Friedman-Mazursky; Matanya Tirosh; Gabriel Chodick; Avi Leader
Journal:  Res Pract Thromb Haemost       Date:  2022-05-23

Review 3.  Management of venous thromboembolism with non-vitamin K oral anticoagulants: A review for nurse practitioners and pharmacists.

Authors:  Michelle Schmerge; Sally Earl; Carol Kline
Journal:  J Am Assoc Nurse Pract       Date:  2018-04       Impact factor: 1.165

4.  Systematic literature review of treatment patterns for venous thromboembolism patients during transitions from inpatient to post-discharge settings.

Authors:  Jeffrey Trocio; Virginia M Rosen; Anu Gupta; Oluwaseyi Dina; Lien Vo; Patrick Hlavacek; Lisa Rosenblatt
Journal:  Clinicoecon Outcomes Res       Date:  2018-12-19

5.  Non-compliance with clinical guidelines increases the risk of complications after primary total hip and knee joint replacement surgery.

Authors:  Helen Mary Badge; Tim Churches; Justine M Naylor; Wei Xuan; Elizabeth Armstrong; Leeanne Gray; John Fletcher; Iain Gosbell; Christine Lin; Ian A Harris
Journal:  PLoS One       Date:  2021-11-18       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.